Research and Clinical Trials

Title  
Eli Lilly I5B-MC-JGDN: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin in Pediatric Patients with Advanced or Metastatic Cancer
Brief Description  
The primary objective of this study is to determine a safe dose of olaratumab alone or in combination with chemotherapy regimens that can be administered to pediatric patients.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Soft Tissue
Status  
OPEN
Start Date  
03/01/2017
IRB Number  
00018380
Principal Investigator  
Jacobsen, Chad Thomas
Contact Name  
Gerri Robinson

For More Information, Contact  Gerri  , Robinson
Phone:  980-442-2355 Fax:    
Email:  gerri.robinson@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close